Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance)
   Google Scholar   
Citation:
J. Clin. Oncol. vol 34 (4s) abstr 192
Meeting Instance:
ASCO GI 2016
Year:
2016
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
ppub
Note:
Corresponding Author: Ghassan Abou-Alfa
Methodological:
No
Biospecimen:
No
DataSharing:
No
Parents:
None
Children:
3009  
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
Bayer Healthcare; Berlex  
Grants:
U10CA180821, U10CA180882  
Corr. Author:
 
Authors:
                                         
Primary Study
CALGB-80802
Secondary Studies:
Phases:
3
Keywords:
Sorafenib